Landmark Large-scale Publication Shows SneakPeek Early Gender DNA Test Predicts Fetal Sex with 99.9% Accuracy, Months Before Ultrasound

LA JOLLA, Calif., Jan. 12, 2021 /PRNewswire-PRWeb/ -- Gateway Genomics, leading provider of direct-to-consumer genetic tests focused on prenatal and pediatric information, announces a new publication titled, "Large scale follow-up research study: SneakPeek® Early Gender DNA Test 99.9% accurate for fetal sex by live-birth confirmation" in the International Journal of Pregnancy & Child Birth.

In the study, 1,029 women between 7 and 37 weeks of gestation purchased and took the commercially-available SneakPeek test between October and December 2019, providing venipuncture samples which were sent to SneakPeek Labs and analyzed by SneakPeek's standard qPCR method. After birth, the study participants were surveyed to determine if fetal sex at birth matched the SneakPeek test result. SneakPeek matched birth sex in 1028 of the 1029 instances, providing 99.9% accuracy, making it the most dependable and reliable early fetal sex test on the market.

"This research is in line with previous studies conducted to ensure we're providing extremely accurate results for our customers," says Gateway Genomics CEO, Chris Jacob. "In previous publications, the SneakPeek Early Gender DNA Test was consistently over 99% accurate, and we're thrilled to see that with many years of hard work and improvement of our test process and technology, we're now able to provide 99.9% accuracy. It's a testament to our employees' commitment to using innovation to provide the most accurate and easy to use test on the market for our SneakPeek moms."

Of 1,029 samples from women 7-37 weeks into pregnancy (median = 10 weeks), 1,028 SneakPeek test results matched the baby's gender at birth for an overall accuracy of 99.9%. Y-chromosome DNA was detected in 505 of the 506 samples from mothers that gave birth to baby boys, providing 99.8% sensitivity. Gender of all 523 newborn girls was identified correctly, resulting in 100% specificity. There were no cases of male DNA contamination in this study (i.e., no false positives).

"Normally in studies like this, instead of waiting for live birth, results are often cross-checked with another fetal-DNA based method such as next-generation sequencing (NGS), which in itself can have errors," continues Mr. Jacob. "That means you're confirming your test method without actually knowing the sex of the fetus. In waiting for the live birth of these babies, we're using the only true and accurate way to measure the performance of a gender prediction test."

In 2020, Gateway Genomics ranked #296 in the Inc. 5000 list of fastest-growing private companies in the U.S., #22 in the Health sector. In 2020's Inc. 5000 California list, the company was ranked the 17th fastest-growing private company in the state, and #1 in the Health sector. Gateway Genomics' principal product, SneakPeek, is an easy-to-use DNA test that lets parents know the gender of their babies as early as 8 weeks into pregnancy, with 99.9% accuracy.

About Gateway Genomics

Gateway Genomics is a personal genomics company with the mission to develop leading-edge genetic tests that give families a new level of understanding about their future children. Since inception, more than 300,000 SneakPeek Early Gender DNA tests have been provided to help new parents bond with their babies, make plans, and connect with friends and family around them. Gateway Genomics is located in La Jolla, CA.

Media Contact

Angela Shue, Gateway Genomics, 8582554330, [email protected]

SOURCE Gateway Genomics